Supplementary Figure 1 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiangfeng Luo,Yiliang Zhang,Bin Peng,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yu Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461807.v1

2023-01-01

Abstract:FGFR3-TACC3 fusion variants and BAG4-FGFR1 fusion in NSCLCs

What problem does this paper attempt to address?

Supplementary Table 4 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461768

2023-01-01

Abstract:Independent predictors of FGFR1/3 fusions in 1328 patients with NSCLCs in multivariate analysis
Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461774.v1

2023-01-01

Abstract:Clinicopathologic Characteristics in NSCLC Patients with FGFR, ALK, RET and ROS1 fusions
Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461759.v1

2023-01-01

Abstract:PDF file - 56KB, Correlation between FGFR fusion and expression.
Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461762.v1

2023-01-01

Abstract:Table 5:Correlation between FGFR fusion and expression Table 6: Clinicopathologic Characteristics of 734 Patients with NSCLC in Survival analysis
Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461795

2023-01-01

Abstract:Kaplan-Meier survival curves for relapse free and overall survival according to EGFR, KRAS, BRAF, HER2, FGFR or wild-type status
Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.ccr-14-0284

2014-01-01

Abstract:Abstract Purpose: The fibroblast growth factor receptor (FGFR)-3 fusion genes have been recently demonstrated in a subset of non–small cell lung cancer (NSCLC). To aid in identification and treatment of these patients, we examined the frequency, clinicopathologic characteristics, and treatment outcomes of patients who had NSCLC with or without FGFR fusions. Experimental Design: Fourteen known FGFR fusion variants, including FGFR1, FGFR2, and FGFR3, were detected by RT-PCR and verified by direct sequencing in 1,328 patients with NSCLC. All patients were also analyzed for mutations in EGFR, KRAS, HER2, BRAF, ALK, RET, and ROS1. Clinical characteristics, including age, sex, smoking status, stage, subtypes of lung adenocarcinoma, relapse-free survival, and overall survival, were collected. Results: Of 1,328 tumors screened, two (0.2%) were BAG4-FGFR1 fusion and 15 (1.1%) were FGFR3-TACC3 fusion. Six of 1,016 patients with lung adenocarcinoma were FGFR3-TACC3 fusions and 11 of 312 lung squamous cell carcinoma harbored BAG4-FGFR1 or FGFR3-TACC3 fusions. Compared with the FGFR fusion-negative group, patients with FGFR fusions were more likely to be smokers (94.1%, 16 of 17 patients, P < 0.001), significantly associated with larger tumor (>3 cm; 88.2%, 15 of 17 patients, P < 0.001) and with a tendency to be more poorly differentiated (53.9%, nine of 17 patients, P = 0.095). Conclusions:FGFR fusions define a molecular subset of NSCLC with distinct clinical characteristics. FGFR is a druggable target and patients with FGFR fusions may benefit from FGFR-targeted therapy, which needs further clinical investigation. Clin Cancer Res; 20(15); 4107–14. ©2014 AACR.
Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Xiuyu Cai,Chunwei Xu,Wen Xian Wang,Quxia Zhang,Yu Chen,Yong Fang,Hong Wang,You-cai Zhu,Wu Zhuang,Yun-jian Huang,Yinbin Zhang,Liping Wang,Yafei Wang,Meifang Chen,Dongyong Yang,Shangli Cai,Meiyu Fang,Gang Chen,Tangfeng Lv,Yong Song

DOI: https://doi.org/10.1200/jco.2019.37.15_suppl.e13001

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:e13001 Background: Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in non-small cell lung cancer (NSCLC) biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. The aim of this study was to evaluate the prevalence of FGFR-TACC fusions in Chinese NSCLC populations, which had not been reported earlier, and to describe targeting potential in Chinese NSCLC populations. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2018. Capture-based comprehensive genomic profiling was performed on 2743 NSCLC FFPE samples sequenced to a mean coverage depth of > 650X for up to 381 cancer-related genes. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.2 Mb of sequenced DNA. Results: Of this entire cohort, just 16 (0.58%) patients were identified with FGFR-TACC fusions, including FGFR1-TACC 1 fusion (1), FGFR2-TACC2 fusion (3) and FGFR3-TACC3 fusion (12). Median patient age was 57 (range 36-84 years). Of the FGFR-TACC fusion NSCLC patients, 56.25% were detected in female patients. Biopsies were obtained from primary lung tumor (31.25%) and metastatic sites (68.75%). Overall TMB in the FGFR-TACC fusion was low (median 3.6 mut/Mb), although two cases (12.50%) had > 20 mut/Mb. Of the FGFR-TACC fusion NSCLC patients, two cases (12.50%) featured EGFR SV alterations. Conclusions: FGFR-TACC fusions occur in a subset of patients with NSCLC. Such patients should be considered for clinical trials featuring FGFR inhibitors (AZD4547). Moreover, NGS can provide information for targeted therapy. For NSCLC patients to benefit from more personalized cancer treatment, clinical therapy should improve with clinical diagnostics through multi-gene assays to determine the actual clinical benefits.
Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing

Xuefei Zhang,Yanlin Li,Changhong Liu,Weifeng Wang,Mo Li,Desheng Lv,Ge Sun,Hui Chen,Xiaowei Dong,Zhibo Miao,Ming Yao,Kai Wang,Hui Tian

DOI: https://doi.org/10.1016/j.lungcan.2017.08.019

IF: 6.081

2018-01-01

Lung Cancer

Abstract:Objectives RET fusions have been reported in 1–2% of lung adenocarcinomas, and represent an actionable target. Patients whose tumors possess RET fusion are associated with clinical benefit from the treatment with multi-kinase inhibitors such as cabozantinib and vandetanib. Further molecular screening for RET fusions is warranted. Novel KIF13A-RET fusion containing an intact RET kinase domain involving exons 1–18 of KIF13A and exons 12–20 of RET was identified in a lung cancer specimen from an 74-year-old Asian never smoker by next-generation sequencing (NGS) during clinical care. The patient was negative for EGFR, ALK, ROS1 and other putative driver alterations. Fusion analysis is consistent with other described RET fusions and is predicted to result in aberrant constitutive activation caused by dimerization and sensitivity to RET-directed therapies. We describe a novel RET-fusion with molecular characteristics consistent with RET-driven non-small cell lung cancer. Our case expands the spectrum of RET fusion partners and supports broad molecular profiling in non-small cell lung cancer optimizing patient therapeutic options. The new RET fusion has immediate clinical implications for cancer patients.
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of NSCLC

Rui Wang,Haichuan Hu,Yunjian Pan,Yuan Li,Ting Ye,Chenguang Li,Xiaoyang Luo,Lei Wang,Hang Li,Yang Zhang,Fei Li,Yongming Lu,Qiong Lu,Jie Xu,David Garfield,Lei Shen,Hongbin Ji,William Pao,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1200/jco.2012.44.1477

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:Purpose The RET fusion gene has been recently described in a subset of non–small-cell lung cancers (NSCLCs). Because we have limited knowledge about these tumors, this study was aimed at determining the clinicopathologic characteristics of patients with NSCLC harboring the RET fusion gene. Patients and Methods We examined the RET fusion gene in 936 patients with surgically resected NSCLC using a reverse transcriptase polymerase chain reaction (PCR) plus quantitative real-time PCR strategy, with validation using immunohistochemical and fluorescent in situ hybridization assays. A subset of 633 lung adenocarcinomas was also studied for EGFR, KRAS, HER2, and BRAF mutations, as well as ALK rearrangements. Patient characteristics, including age, sex, smoking history, stage, grade, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of subtypes of lung adenocarcinoma, and relapse-free survival, were collected. Results Of 936 patients with NSCLC, the RET fusion gene was exclusively detected in 13 patients (11 of 633 patients with adenocarcinomas and two of 24 patients with adenosquamous cell carcinomas). Of the 13 patients, nine patients had KIF5B-RET, three patients had CCDC6-RET, and one patient had a novel NCOA4-RET fusion. Patients with lung adenocarcinomas with RET fusion gene had more poorly differentiated tumors (63.6%; P = .029 for RET v ALK, P = .007 for RET v EGFR), with a tendency to be younger (≤ 60 years; 72.7%) and never-smokers (81.8%) and to have solid subtype (63.6%) and a smaller tumor (≤ 3 cm) with N2 disease (54.4%). The median relapse-free survival was 20.9 months. Conclusion RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics, warranting further clinical consideration and targeted therapy investigation.
Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

Lei WANG,Feng-qing HU,Li-fei MENG,Ming-song WANG,Guo-qing LI,Ju MEI

DOI: https://doi.org/10.13241/j.cnki.pmb.2018.05.014

2018-01-01

Abstract:Objective:To explore the FGFR fusion and its clinical significance in the lung squamous cell carcinoma and adenocarcinoma.Methods:The retrospective series of NSCLCs were investigated for FGFR fusion by reverse transcriptase polymerase chain reaction (RT-PCR) followed by direct sequencing from January 2011 to December 2013.All patients were also analyzed for EGFR,KRAS,HER2 and BRAF mutations.Results:512 cases were enrolled to our study including 119 squamous cell carcinoma and 393 adenocarcinoma.We found that 1.2％ of the cases harbored FGFR fusion.Compared to the FGFR-negative group,patients with FGFR fusion were more likely to be male(p=0.028) smokers(p=0.038),significantly associated with squamous cell carcinoma(p=0.029),more likely to have large tumor (＞3 cm) (p=0.029).Moreover,There were no significant differences in RFS or OS between patients with and without FGFR fusions.Conclusion:FGFR fusions identified a distinct subset of NSCLC with a higher prevalence among smokers with squamous cell carcinoma and relative larger tumor (＞3 cm).This part of our study provided a clinical reference in targeted therapy screening with non-small cell lung cancer and was helpful for anticipating the prognosis in Chinese NSCLC patients.
A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Weidong Wang,Wang Lv,Hui Wang,Yang Xu,Junrong Yan,Han-Ming Shen,Liqun Shan,Jian Hu

DOI: https://doi.org/10.1016/j.gendis.2023.02.019

IF: 7.376

2023-01-01

Genes & Diseases

Abstract:Around 10％-30％ of non-small cell lung cancer(NSCLC)patients harbored epidermal growth factor receptor(EGFR)mutations,with L858R and exon-19 deletions(19-Del)ac-counting for 90％of cases.EGFR tyrosine kinase inhibitors(TKIs)showed significant efficacy against common EGFR mutations.However,the therapeutic relevance of uncom-mon EGFR mutations remained insufficiently investigated.
Identification of TRA2B-DNAH5 Fusion As a Novel Oncogenic Driver in Human Lung Squamous Cell Carcinoma

Fei Li,Zhaoyuan Fang,Jian Zhang,Chen Li,Hongyan Liu,Jufeng Xia,Hongwen Zhu,Chenchen Guo,Zhen Qin,Fuming Li,Xiangkun Han,Yuetong Wang,Yan Feng,Ye Wang,Wenjing Zhang,Zuoyun Wang,Yujuan Jin,Yihua Sun,Wenyi Wei,Rong Zeng,Haiquan Chen,Hongbin Ji

DOI: https://doi.org/10.1038/cr.2016.111

IF: 44.1

2016-01-01

Cell Research

Abstract:Lung squamous cell carcinoma (SCC) is one of the major subtypes of lung cancer. Our current knowledge of oncogenic drivers in this specific subtype of lung cancer is largely limited compared with lung adenocarcinoma (ADC). Through exon array analyses, molecular analyses and functional studies, we here identify the TRA2B-DNAH5 fusion as a novel oncogenic driver in lung SCC. We found that this gene fusion occurs exclusively in lung SCC (3.1%, 5/163), but not in lung ADC (0/119). Through mechanistic studies, we further revealed that this TRA2B-DNAH5 fusion promotes lung SCC malignant progression through regulating a SIRT6-ERK1/2-MMP1 signaling axis. We show that inhibition of ERK1/2 activation using selumetinib efficiently inhibits the growth of lung SCC with TRA2B-DNAH5 fusion expression. These findings improve our current knowledge of oncogenic drivers in lung SCC and provide a potential therapeutic strategy for lung SCC patients with TRA2B-DNAH5 fusion.
FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity

Abbas Agaimy,Cristina R. Antonescu,Diana Bell,Gerben E. Breimer,Josephine K. Dermawan,Lennart A. Kester,Jan Laco,Johannes A. Rijken,Rumeal D. Whaley,Robert Stoehr,Thomas Cramer,Justin A. Bishop

DOI: https://doi.org/10.1007/s00428-024-03940-3

2024-10-12

Virchows Archiv

Abstract:The FGFR3 :: TACC3 fusion has been reported in subsets of diverse cancers including urothelial and squamous cell carcinomas (SCC). However, the morphology of FGFR3 :: TACC3 -positive head and neck carcinomas has not been well studied and it is unclear if this fusion represents a random event, or if it might characterize a morphologically distinct tumor type. We describe nine FGFR3 :: TACC3 fusion–positive head and neck carcinomas affecting six males and three females aged 38 to 89 years (median, 59). The tumors originated in the sinonasal tract ( n = 4), parotid gland ( n = 2), and one case each in the oropharynx, submandibular gland, and larynx. At last follow-up (9–21 months; median, 11), four patients developed local recurrence and/or distant metastases, two died of disease at 11 and 12 months, one died of other cause, one was alive with disease, and two were disease-free. Three of six tumors harbored high risk oncogenic HPV infection (HPV33, HPV18, one unspecified). Histologically, three tumors revealed non-keratinizing transitional cell-like or non-descript morphology with variable mixed inflammatory infiltrate reminiscent of mucoepidermoid or DEK :: AFF2 carcinoma (all were HPV-negative), and three were HPV-associated (all sinonasal) with multiphenotypic (1) and non-intestinal adenocarcinoma (2) pattern, respectively. One salivary gland tumor showed poorly cohesive large epithelioid cells with prominent background inflammation and expressed AR and GATA3, in line with a possible salivary duct carcinoma variant. Two tumors were conventional SCC. Targeted RNA sequencing revealed an in-frame FGFR3 :: TACC3 fusion in all cases. This series highlights heterogeneity of head and neck carcinomas harboring FGFR3 :: TACC3 fusions, which segregates into three categories: (1) unclassified HPV-negative category, morphologically distinct from SCC and other entities; (2) heterogeneous group of HPV-associated carcinomas; and (3) conventional SCC. A driver role of the FGFR3 :: TACC3 fusion in the first category (as a potential distinct entity) remains to be further studied. In the light of available FGFR -targeting therapies, delineation of these tumors and enhanced recognition is recommended.

pathology
1148P Identification and Validation of RET Fusions in Lung Adenocarcinoma Through DNA and RNA Sequencing

Y. Han,C. Xiang,L. Guo,R. Zhao,A. Yu

DOI: https://doi.org/10.1016/j.annonc.2021.08.789

IF: 51.769

2021-01-01

Annals of Oncology

Abstract:RET fusion has emerged as a targetable oncogenic driver in non-small cell lung cancer. The optimal methods to identify actionable RET fusions during clinical practice remain to be evaluated. Herein, we performed a comparative analysis on RET fusions using targeted next-generation sequencing at DNA (DNA-seq) and RNA (RNA-seq) levels. A total of 53 lung adenocarcinoma patients harboring non-canonical RET fusions identified by DNA-seq were selected to receive RNA-seq of their remaining tumor samples using a 115-cancer gene panel (OncoRNA). Of them, 43 passed quality control of RNA-seq. The breakpoints and partners of RET-fusion identified by DNA- and RNA-Seq were described and compared. Of the 43 patients, DNA-seq identified 25 patients with concurrent 5’ RET fusions and 3’ canonical RET fusions (KIF5B-RET (K15:R12) or CCDC6-RET (C1:R12), subgroup A), 2 patients with 5’ RET fusions alone (subgroup B), 8 patients with frameshift or out-of-frame fusions (subgroup C) and 8 patients with 3’ non-canonical RET fusions alone (subgroup D). In total, 40 of 43 patients (93%) were positive for RET-fusions at RNA level. In subgroup A, RNA-seq detected all canonical RET-fusions with identical breakpoints to DNA-seq, while no transcripts of the 5’ RET fusions were detected. Patients in subgroups B and C did not have in-frame actionable fusions detected by DNA-seq. However, in subgroup B, RNA-seq identified 1 KIF5B-RET transcript with rare breakpoint (K24:R10). In subgroup C, only 1 patient was negative while 7 patients were positive at RNA level including 6 with canonical RET fusions of which the RET breakpoints were identical to DNA-seq. The discordance might be explained by complex DNA structural rearrangements and RNA splicing. In subgroup D, RNA-seq identified 7 of 8 patients with RET fusions concordant with DNA-seq, and 1 patient was negative. Most RET fusions in this subgroup involved rare partners including KIAA1468, LMNA, TRIM33, EDC4, ANKRD26, and AKAP13. DNA-seq and RNA-seq showed high consistency in detecting RET fusions. RNA-seq could be valuable in determining the actionability of 5’ or frameshift/out-of-frame DNA fusions.
Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing

Weiquan Gu,Jie Yang,Yong Wang,Jun Xu,Xiaoxuan Wang,Furong Du,Xiangjing Hu,Hao Guo,Chao Song,Rongjie Tao,Xuchao Zhang

2021-08-15

Abstract:Deregulation of fibroblast growth factor receptor (FGFR) network is common in cancer due to activating mutations, gene amplifications and chromosomal translocations. Currently, various FGFR inhibitors are being developed. In order to optimize their clinical applications, understanding the frequencies and types of FGFR alterations in multiple cancer types appears to be extremely important. This study characterized FGFR1-4 alterations in solid tumors by next-generation sequencing (NGS). Between Jun. 2019 and Aug. 2020, the sequencing data of 5 557 solid tumors of diverse types in the database of Simcere Diagnostics, Inc. (Nanjing, China) were retrospectively analyzed. A panel-based NGS assay was used to detect FGFR1-4 alterations in tumor samples. 9.2% of cancer cases had FGFR1-4 alterations, in which gene amplifications (51.5%) and mutations (40.7%) were frequent, whereas gene rearrangements were less common (10.0%). FGFR1 was involved in 4.6% of 5 557 cases, FGFR2 in 2.1%, FGFR3 in 1.6%, and FGFR4 in 1.4%. Of patients with FGFR1-4 alterations, TP53, MUC16, NSD3, MYC and LRP1B genes were the top 5 mutant genes. FGFR1-4 aberrations occurred in almost every type of solid tumors, with the most common tumor being endometrial carcinoma (22.2%), followed by sarcoma (17.3%), breast cancer (13.2%), gastric cancer (12.2%), and more. 0.6% of cancer cases harbored FGFR1-4 fusions, with the most common fusion partner being TACC3. Two cases of GBM harboring FGFR3-TACC3 fusions were responsive to anlotinib treatment. In conclusion, FGFR1-4 alterations are prevalent in solid tumors of diverse types, with the majority being gene amplifications and mutations. FGFR1-4 fusions only occur in a minority of cancer cases, and those with glioblastoma harboring FGFR3-TACC3 fusions may benefit from anlotinib.
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

Devendra Singh,Joseph Minhow Chan,Pietro Zoppoli,Francesco Niola,Ryan Sullivan,Angelica Castano,Eric Minwei Liu,Jonathan Reichel,Paola Porrati,Serena Pellegatta,Kunlong Qiu,Zhibo Gao,Michele Ceccarelli,Riccardo Riccardi,Daniel J. Brat,Abhijit Guha,Ken Aldape,John G. Golfinos,David Zagzag,Tom Mikkelsen,Gaetano Finocchiaro,Anna Lasorella,Raul Rabadan,Antonio Iavarone

DOI: https://doi.org/10.1126/science.1220834

IF: 56.9

2012-09-07

Science

Abstract:Oncogenic TACC-tics Human cancers exhibit many types of genomic rearrangements—including some that juxtapose sequences from two unrelated genes—thereby creating fusion proteins with oncogenic activity. Functional analysis of these fusion genes can provide mechanistic insights into tumorigenesis and potentially lead to effective drugs, as famously illustrated by the BCR-ABL gene in chronic myelogenous leukemia. Singh et al. (p. 1231 , published online 26 July) identify and characterize a fusion gene present in 3% of human glioblastomas, a deadly brain cancer. In the resultant fusion protein, the tyrosine kinase region of the fibroblast growth factor receptor (FGFR) is joined to a domain from a transforming acidic coiled-coil (TACC) protein. The TACC-FGFR protein is oncogenic, shows unregulated kinase activity, localizes to the mitotic spindle, and disrupts chromosome segregation. In mice, FGFR inhibitors slowed the growth of tumors driven by the TACC-FGFR gene, suggesting that a subset of glioblastoma patients may benefit from these types of drugs.

multidisciplinary sciences
P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

H. Wang,C. Xu,W. Wang,Q. Zhang,W. Zhuang,Y. Zhu,Y. Huang,Y. Chen,G. Chen,M. Fang,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.687

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Mutations of the fibroblast growth factor receptor 1 (FGFR1) is believed to predict response to FGFR inhibitors, but the genetic spectrum of FGFR1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring FGFR1 mutations. A total of 469 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of FGFR1 mutation and other genes were detected by next generation sequencing. FGFR1 gene mutation rate was 2.99% (14/469) in non-small cell lung cancer, including S99L (3 patients), S107L (2 patients), N546K (1 patient), R756H (1 patient), G70R (1 patient), R661Q (1 patient), V94I (1 patient), R50Q (1 patient), D312V (1 patient), R6Q (1 patient) and M427V (1 patient), and median overall survival (OS) for these patients was 11.4 months. Among them, all patients were FGFR1 gene with co-occurring mutation. Briefly, patients with (n=3) or without (n=11) co-occurring EGFR mutations had a median OS of 16.7 months and 11.0 months respectively (P=0.56); patients with (n=11) or without (n=3) co-occurring TP53 mutations had a median OS of 11.4 months and 20.7 months respectively (P=0.48); patients with (n=2) or without (n=12) co-occurring STK11 mutations had a median OS of 5.0 months and 11.4 months respectively (P=0.57); patients with (n=3) or without (n=11) co-occurring PTCH1 mutations had a median OS of 5.7 months and 11.4 months respectively (P=0.11). It demonstrated that FGFR1 mutation was an infrequent genetic alteration, and for firstly, and we found FGFR1 mutation also was an independent delayed adverse prognostic factor only in early stage NSCLC patients, suggesting that FGFR1 mutation may be a viable prognostic factor in these patients.
P73.01 Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations

W. Wang,C. Xu,D. Wang,Y. Zhu,W. Zhuang,M. Fang,T. Lv,Y. Song

DOI: https://doi.org/10.1016/J.JTHO.2021.01.1030

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:Activation of the fibroblast growth factor receptor (FGFR) family through fusion with various partners has been described in multiple cancer types, including non-small-cell lung cancer (NSCLC). The aim of this study is to investigate mutations and prognosis of NSCLC harboring FGFR2 mutations.
P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

W. Wang,C. Xu,Y. Zhu,Y. Liu,Y. Chen,Q. Zhang,H. Wang,W. Zhuang,X. Chen,J. Lai,M. Fang,Y. Tao,S. Xu,X. Qian,H. Zhao,S. Cai,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.1196

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:NTRK fusions have been recently identified as a therapeutic target in a rare fraction of Caucasian patients with lung cancer (3.3%). The aim of this study was to evaluate the prevalence of NTRK fusions in Chinese lung cancer populations, which had not been reported earlier, and to describe targeting potential in Chinese lung cancer populations. A multicenter study in China was initiated from February 2014, and lung cancer patients have been enrolled as of December 2017. Capture-based comprehensive genomic profiling was performed on 2719 lung cancer FFPE samples (non-squamous/squamous/small=2061/349/309) sequenced to a mean coverage depth of > 650X for up to 381 cancer-related genes. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.2 Mb of sequenced DNA. Of this entire cohort, just one (0.04%) patient was identified with a TPM3-NTRK1 fusion. The patient was diagnosed with SCLC. TPM3-NTRK1 fusion was found by biopsy using NGS, the genes co-altered with NTRK fusion was no concurrent with KRAS, EGFR, ALK, ROS1, or other known drivers were identified in the study cohort cases. NTRK fusions are a rare molecular subtype in Chinese lung cancer populations. Given clinical evidence for the activity of targeted therapy approaches, molecular eligibility for clinical trials of larotrectinib or entrectinib should include these fusion subtypes. The clinical evidence for responsiveness of NTRK fusions driven lung cancer provides an opportunity to personalize treatments and improve clinical outcomes for patients.
Supplementary Table 3 from TGFBR1 Haplotypes and Risk of Non–Small-Cell Lung Cancer

Zhe Lei,Reng-Yun Liu,Jun Zhao,Zeyi Liu,Xiefang Jiang,Weiming You,Xiao-Feng Chen,Xia Liu,Kui Zhang,Boris Pasche,Hong-Tao Zhang

DOI: https://doi.org/10.1158/0008-5472.22379141

2023-01-01

Abstract:Supplementary Table 3 from TGFBR1 Haplotypes and Risk of Non–Small-Cell Lung Cancer

Supplementary Figure 1 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 4 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of NSCLC

Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Identification of TRA2B-DNAH5 Fusion As a Novel Oncogenic Driver in Human Lung Squamous Cell Carcinoma

FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity

1148P Identification and Validation of RET Fusions in Lung Adenocarcinoma Through DNA and RNA Sequencing

Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

P73.01 Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

Supplementary Table 3 from TGFBR1 Haplotypes and Risk of Non–Small-Cell Lung Cancer